Pioneering botulism antitoxin from Cangene gets FDA nod

03/25/2013 | Medscape (free registration) · Reuters

The FDA approved Cangene's Botulism Antitoxin Heptavalent to treat patients with suspected or documented exposure to all known botulinum neurotoxin serotypes. The horse plasma-based antitoxin is the only botulism treatment available for adults and for infants whose illness was caused by toxins other than types A and B. Because the drug holds an orphan-drug designation, it will get seven years of market exclusivity.

View Full Article in:

Medscape (free registration) · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC